# CHRN earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/CHRN) · [Earnings tab](https://www.lopjlb.com/stock/CHRN?tab=earnings)

Updated: 2026-08-17T09:29:38

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly call summaries, Ekso Bionics has shifted from early revenue acceleration and nascent CMS rule anticipation (2023 Q3) to a mixed picture of modest top‑line growth, improving margins, and heightened reliance on personal‑health reimbursement pathways. The company secured multiple CMS and Medicare reimbursements for its Indego/Indigo Personal devices, turning a key regulatory uncertainty into a delivered milestone, while enterprise health sales have faltered amid capital‑budget cuts and IDN procurement timing. Gross margins rose from the low‑50s to a peak of 54% before compressing to 40% as enterprise volume fell and lower‑margin distribution sales grew. Operating expenses have been trimmed consistently, supporting a move toward cash‑flow breakeven, yet cash balances have fluctuated, prompting equity raises and modest capital raises. International demand, especially in Europe, remains a growth engine, supported by expanding distribution networks. New initiatives—AI/NVIDIA partnership, eksoUniversity, and expanded O&P distributors—signal a strategic pivot toward scalable personal‑health commercialization, while fears around reimbursement timing, enterprise budget softness, and IDN cycle volatility persist throughout the period.

## Latest CallCard · Q2

Ekso Bionics Q2 revenue fell 58% to $2.1M due to delayed Enterprise Health deals; Personal Health grew >50% YoY; confident on H2 recovery and AI-driven growth.

**Guidance:** vague — No formal guidance provided; management expects to close deferred Enterprise sales in H2 and sees Personal Health reaching ~25% of revenue in 2025.

**Tone:** mgmt 0.3 · Q&A pressure 0.4 · divergence 0.1

Management called Q2 'disappointing' but 'temporary setback,' expressed confidence in closing deferred Enterprise deals in H2, highlighted >50% Personal Health growth, and emphasized AI/NVIDIA partnership as growth pillar.

### Demand visibility

Enterprise Health demand delayed by grant losses and budget concerns; Personal Health pipeline growing rapidly with >45 qualified Medicare candidates.

Two large Enterprise deals ($1.4M) deferred to H2; ~10% of Enterprise customers rely on federal grants; Personal Health pipeline up >200% to >45 Medicare beneficiaries; new distribution partnerships with NSM and Bionic P&O driving lead generation.

### Margins / costs

Gross margin compressed to 40% from 53% due to fixed costs on lower Enterprise volume, lower-margin distribution sales, and higher shipping; OpEx improved 4%.

Gross profit $800K (40% margin) vs $2.6M (53%); decline driven by fixed COGS on lower Enterprise sales, lower-margin distribution volume, higher shipping; partially offset by improved service margins. Operating expenses $4.8M, down 4% YoY.

### Capital allocation

Focused on AI/NVIDIA partnership, eksoUniversity platform, and Personal Health commercialization; cash $5.2M as of June 30.

Investing in NVIDIA Connect program for AI foundation model; launched eksoUniversity for therapist education; partnering with PRIA Healthcare for market access; no mention of buybacks, dividends, or M&A.

### Milestones

- **Deferred Enterprise Health sales closure** [at_risk]: Two multi-unit deals ($1.4M) deferred from Q2; international regulatory challenges and North American IDN expected in Q3
- **Personal Health revenue growth** [on_track]: Personal Health revenues grew >50% YoY in H1 2025; expected ~25% of total revenue in 2025
- **NVIDIA Connect partnership** [delivered]: Joined NVIDIA Connect in mid-May; announced AI voice agent proof of concept 34 days later
- **Ekso Voice Agent (AI)** [delivered]: Proof of concept for EksoNR using NVIDIA Jetson Orin Nano, JetPack SDK, OpenAI tools
- **eksoUniversity launch** [delivered]: Virtual CEU platform launched; first certification delivered to Connecticut PT
- **NSM distribution partnership** [delivered]: First order received from National Seating & Mobility as exclusive CRT distributor
- **Bionic P&O distribution** [delivered]: Named as first O&P distributor; submitted 3 Medicare claims in Q2
- **PRIA Healthcare partnership** [on_track]: Engaged for market access, coding, coverage, payment navigation

## Quarter one-liners

- **2025 Q2:** Ekso Bionics Q2 revenue fell 58% to $2.1M due to delayed Enterprise Health deals; Personal Health grew >50% YoY; confident on H2 recovery and AI-driven growth.
- **2025 Q1:** Ekso Bionics Q1 revenue fell to $3.4M on enterprise budget softness; gross margin improved to 54%; personal health pipeline grows 37% to 35+ Medicare candidates; new distributors NSM and Bionic P&O expand Indego Personal access.
- **2024 Q4:** Ekso Bionics reports Q4 revenue of $5.1M (+5% YoY), full-year revenue down slightly to $17.9M; focuses on scaling Indigo Personal via Medicare reimbursement with Priya Healthcare and NSM distribution, expects personal health contribution to grow in 2025.
- **2024 Q3:** Ekso Bionics reported $4.1M sales, highlighted initial CMS reimbursement for its Indego Personal device, strong European demand, off‑cycle IDN procurement in the U.S., and modest margin improvement driven by supply‑chain savings.
- **2024 Q2:** Ekso Bionics posted record Q2 sales of $5M (37 EksoHealth devices), secured CMS reimbursement for Indego Personal, expanded gross margin to 53%, cut operating expenses 23% YoY, and sees Indego Personal as a multi-billion dollar opportunity with revenue impact expected in 2025.
- **2024 Q1:** Ekso Bionics reports Q1 2024 revenue of $3.8M, gross margin improvement to 52%, and secures Medicare reimbursement of $91,031 for Ekso Indego Personal, driving optimism for Personal Health growth amid international momentum in EMEA.
- **2023 Q4:** Ekso Bionics reports record 2023 revenue $18.3M (+42% YoY) on EksoHealth growth; launched GaitCoach; Indego Personal CMS reimbursement pending; operating leverage improved (expenses +11%); cash $8.6M + $3.9M raise.
- **2023 Q3:** Ekso Bionics posted 38% YoY revenue growth to $4.6M in Q3, driven by 41 EksoHealth device sales and record EVO units; CMS ruling in late November could unlock 164k Medicare/Medicaid patients for Indego Personal.

## Theme arcs

- **CMS/Medicare reimbursement progress** (improving): From rule proposal to multiple reimbursements and claim submissions
- **Personal Health pipeline growth** (improving): Pipeline expanded >45 Medicare candidates and >50% YoY revenue growth
- **Enterprise Health demand volatility** (deteriorating): Budget cuts, grant losses, and delayed deals reduced enterprise sales
- **Gross margin trajectory** (stable): Margins improved to mid‑50s then compressed to 40% as volume fell
- **Operating expense discipline** (improving): Expenses cut 15‑23% YoY across periods
- **Cash balance dynamics** (deteriorating): Cash fell from $9.9M to $5.2M despite expense cuts
- **International demand and distribution** (stable): Europe/EMEA expansion remained on‑track
- **IDN procurement cycle impact** (deteriorating): Fluctuations repeatedly delayed U.S. sales
- **Industrial EVO market adoption** (new): Early shipments and later strike‑related risk
- **AI/NVIDIA partnership and platform launches** (new): Introduced AI voice agent, eksoUniversity, and NVIDIA Connect

## Fear persistence

- **Reimbursement risk (CMS/Medicare)** [recurring]: Uncertainty around claim timing and criteria persists across all periods
- **Cash burn and runway risk** [recurring]: Operating losses and declining cash balances repeatedly highlighted
- **Enterprise capital‑budget softness** [recurring]: Budget cuts and grant losses repeatedly impact enterprise sales
- **IDN procurement cycle variability** [recurring]: Fluctuating purchasing cycles delay U.S. enterprise bookings
- **Industrial EVO market adoption risk** [recurring]: Nascent market and labor strikes create sales uncertainty
- **Distribution partner execution risk** [new]: Reliance on PRIA, NSM, Bionic P&O introduces execution uncertainty
- **International reimbursement/partner risk** [recurring]: European adoption tied to country‑specific reimbursement mechanisms
- **Macro‑economic/political uncertainty** [recurring]: Cited as cause for postponed capital purchases
- **Pricing pressure in Europe** [new]: Lower ASPs could compress margins despite volume growth
- **AI partnership integration risk** [new]: Future impact of NVIDIA and AI tools remains uncertain

## Guidance path

2023 Q3:vague → 2023 Q4:vague → 2024 Q1:vague → 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/CHRN`